Fig 1: ZEB1 and JAK2 are potential targets for the treatment of MS(A) Dot plot showing linear correlation of ZEB1 gene expression with JAK2 gene expression in myelin-reactive Th17 cells from MS patients (Th17 MS) and healthy controls (Th17 Ctrl).(B) Contour plots showing sorting strategy for CD3+CD4+CD45RO+CCR6-CXCR3+ (Th1), CD3+CD4+CD45RO+CCR6+CXCR3+ (Th1/Th17), and CD3+CD4+CD45RO+CCR6+CXCR3- (Th17) cells from PBMC of MS patients (Silveira-Mattos et al., 2019).(C–H) Flow cytometry evaluating IFN-? and IL-17A expression in CCR6-CXCR3+ (Th1), CCR6+CXCR3+ (Th1/Th17), and CCR6+CXCR3- (Th17) transfected with siCTL, siJAK2, or siCTL. n = 3 different MS patients.(I) Schematic displaying the experimental design for treating EAE using fedratinib.(J) Clinical scores of C57BL/6 mice treated with vehicle or fedratinib (90 mg/kg) in EAE (n = 15 mice per group). Statistic difference is tested by nonparametric Mann-Whitney test.(K) Flow cytometry evaluating the number of CD4+ cells, CD4+IFN-?+ cells, CD4+IL-17A+ cells, CD4+GM-CSF+cells, CD4+IL4+ cells, CD4+CD25+FOXP3+ cells, CD8+ cells, and CD8+IFN-?+ cells in the CNS of mice treated with vehicle or fedratinib at 29 days post immunization.All statistical differences in (D), (F), (H), and (K) were tested using paired Student’s t test (two-tailed). NS, not significant; *p < 0.05, **p < 0.01.